India, Sept. 17 -- Biotech stocks were in focus Thursday following a series of company updates, including Aethlon Medical's proposed merger with North Immunology, Tiziana Life Sciences' MS trial collaboration, Capricor's upcoming Duchenne data, Firefly Neuroscience's brain-medicine partnership and Clearmind Medicine's FDA psychedelic hearing participation.
Read on.
Aethlon Medical, Inc. (AEMD) shares are surging over 360% after the company announced a definitive all-stock merger with North Immunology, along with an oversubscribed $180 million private placement. The transaction will provide capital to advance NOR-101, an investigational IL-13 x IL-18 bispecific antibody for atopic dermatitis and other immune-mediated diseases. The combined...